BLUE BELL, PA — inTRAvent Medical has announced the appointment of Dr. Adam S. Arthur, MD, MPH, as Chief Clinical Strategy Officer (CCSO). Dr. Arthur will play a pivotal role in shaping the company’s clinical strategy as it prepares for the launch of SOLOPASS®, its advanced platform for external ventricular drain (EVD) placement. He will also guide the development of minimally invasive applications aimed at improving neurocritical care practices.
Dr. Arthur is a renowned expert in cerebrovascular and endovascular neurosurgery, currently serving as the James T. Robertson Endowed Professor and Chair of Neurosurgery at the University of Tennessee Health Science Center and practicing at the Semmes Murphey Clinic. With extensive experience in leading clinical trials such as the WEB-IT, STEM, and MIND studies, Dr. Arthur has established himself as a key advocate for innovative approaches that enhance patient outcomes.
SOLOPASS®, cleared by the FDA, integrates real-time ultrasound imaging, frameless fixation, and a rigid guidance mechanism, enabling precise localization and navigation during EVD procedures. Designed specifically for critical-care environments, the system overcomes the limitations of traditional navigation technologies, which can rely on outdated preoperative imaging compromised by brain shift or evolving conditions.
“Bringing advanced neuronavigation featuring real-time imaging to the bedside has the potential to change the standard of care for EVD placement,” said Dr. Arthur. “Importantly, this platform also creates a pathway for minimally invasive approaches to treating intracranial hemorrhage – without the need to move critically ill patients from the ICU.”
The SOLOPASS system combines 2D and 3D ultrasound imaging with artificial intelligence and trajectory guidance, promising significant advancements in both precision and efficiency for critical neurosurgical procedures.
“Dr. Arthur’s exceptional expertise and forward-thinking approach to neurosurgery make him an invaluable addition to our team,” said Adam Barner, CEO of inTRAvent Medical. “His insights will help guide the continued clinical development of our SOLOPASS® platform to address significant unmet clinical needs.”
Dr. Arthur’s leadership is expected to accelerate inTRAvent’s efforts to transform critical care with innovative, minimally invasive technologies that improve outcomes for neurocritical patients.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.